Median OS, mo
(95% CI)
HR
(97.73% CI)
P
-value
Nivolumab (n = 240)
7.5 (5.5, 9.1)
0.70
(0.51, 0.96)
0.0101
Investigator’s Choice (n = 121)
5.1 (4.0, 6.0)
Overall Survival
Nivolumab in R/M SCCHN After Platinum Therapy
23
Months
Nivolumab
240
167
109
52
24
7
0
Investigator’s
Choice
121
87
42
17
5
1
No. at Risk
0
Overall Survival (% of patients)
0
3
6
9
12
15
18
0
10
20
30
40
50
60
70
80
90
100
1-year OS rate (95% CI)
36.0%
(28.5, 43.4)
16.6%
(8.6, 26.8)
